These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [The kaolin-activated recalcification test in the screening of coagulation disorders and in the control of anticoagulant therapy]. Barberi G; Fiocca S Quad Sclavo Diagn; 1977 Jun; 13(2):167-75. PubMed ID: 594303 [TBL] [Abstract][Full Text] [Related]
26. [Phospholipids and platelet procoagulant activity in myeloproliferative syndromes]. Martínez E; César J; Navarro JL; Mercado A; Pardo A; García Avello A; García Frade J Sangre (Barc); 1985; 30(1):22-7. PubMed ID: 4039850 [No Abstract] [Full Text] [Related]
27. Platelet factor 3 (PF 3) and platelet factor 4 (PF 4) as a guide to platelet membrane structure. O'Brien JR Acta Med Scand Suppl; 1971; 525():87-8. PubMed ID: 5292111 [No Abstract] [Full Text] [Related]
28. Platelet factor 3: a simple assay technique. Saraya AK; Kasturi J; Kishan R Indian J Med Res; 1973 May; 61(5):676-83. PubMed ID: 4763948 [No Abstract] [Full Text] [Related]
29. PARTIAL THROMBOPLASTIN TIME TEST WITH KAOLIN. NORMAL RANGE AND MODIFICATIONS FOR THE DIAGNOSIS OF HAEMOPHILIA AND CHRISTMAS DISEASE. MATCHETT MO; INGRAM GI J Clin Pathol; 1965 Jul; 18(4):465-71. PubMed ID: 14318702 [TBL] [Abstract][Full Text] [Related]
30. [Studies of platelet factor-3 by the kaolin clotting time and thromboplastin generation time]. Oki H; Takashima A Rinsho Byori; 1973 Jul; 21(7):621-6. PubMed ID: 4738067 [No Abstract] [Full Text] [Related]
31. The activity of platelet factor 4 in plasma of healthy and high risk newborns. Alebouyeh M; Unterharnscheidt W; Riegel K Z Kinderheilkd; 1974 Jan; 116(2):137-42. PubMed ID: 4816158 [No Abstract] [Full Text] [Related]
32. Haemostatic profile of reconstituted blood in a proposed 1:1:1 ratio of packed red blood cells, platelet concentrate and four different plasma preparations. Ponschab M; Schöchl H; Gabriel C; Süssner S; Cadamuro J; Haschke-Becher E; Gratz J; Zipperle J; Redl H; Schlimp CJ Anaesthesia; 2015 May; 70(5):528-36. PubMed ID: 25866040 [TBL] [Abstract][Full Text] [Related]
33. [Platelet factor IV (antiheparin factor) and various disease states]. Ulutin ON; Akman N Turk Tip Cemiy Mecm; 1967 Jan; 33(1):61-5. PubMed ID: 6066642 [No Abstract] [Full Text] [Related]
34. Plasma heparin neutralizing activity. Its use in the evaluation of thrombocytopenia and thrombocytosis. Dana B; Carvalho AC; Ellman L Am J Clin Pathol; 1976 Jun; 65(6):964-9. PubMed ID: 945687 [TBL] [Abstract][Full Text] [Related]
35. Effect in vitro on platelet function of two compounds developed from the pyrimido-pyrimidines. Slater SD; Turpie AG; Douglas AS; McNicol GP J Clin Pathol; 1972 May; 25(5):427-32. PubMed ID: 5046075 [TBL] [Abstract][Full Text] [Related]
36. Plasma factor XIII and platelet factor XIII in hyperlipaemia. Cucuianu MP; Miloszewski K; Porutiu D; Losowsky MS Thromb Haemost; 1976 Dec; 36(3):542-50. PubMed ID: 1037152 [TBL] [Abstract][Full Text] [Related]
37. Determination of platelet factor-3 by a modified prothrombin consumption test. Farská I; Pudlák P Scand J Haematol; 1967; 4(3):187-92. PubMed ID: 6048641 [No Abstract] [Full Text] [Related]